about
A healthy bladder: a consensus statementToxin-based therapeutic approachesTyrosine kinase ETK/BMX is up-regulated in bladder cancer and predicts poor prognosis in patients with cystectomyThe Reversal Effect and Its Mechanisms of Tetramethylpyrazine on Multidrug Resistance in Human Bladder CancerThe principal urinary metabolite of allyl isothiocyanate, N-acetyl-S-(N-allylthiocarbamoyl)cysteine, inhibits the growth and muscle invasion of bladder cancerSulforaphane for the chemoprevention of bladder cancer: molecular mechanism targeted approach.Altered expression of transmembrane mucins, MUC1 and MUC4, in bladder cancer: pathological implications in diagnosis.A 20 gene model for predicting nodal involvement in bladder cancer patients with muscle invasive tumors.Pitfalls and Limitations of Diffusion-Weighted Magnetic Resonance Imaging in the Diagnosis of Urinary Bladder Cancer.Comparative mRNA and microRNA expression profiling of three genitourinary cancers reveals common hallmarks and cancer-specific molecular events.Upregulation of long non-coding RNA urothelial carcinoma associated 1 by CCAAT/enhancer binding protein α contributes to bladder cancer cell growth and reduced apoptosisGenetic alterations of chromosomes, p53 and p16 genes in low- and high-grade bladder cancer.Cancer stroma proteome expression profile of superficial bladder transitional cell carcinoma and biomarker discovery.Expression of cyclin d1 and its association with disease characteristics in bladder cancer.Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysisAberrant methylation of CDH13 is a potential biomarker for predicting the recurrence and progression of non muscle invasive bladder cancer.A Review on the Relationship between SGLT2 Inhibitors and Cancer.Deregulation of Rab and Rab effector genes in bladder cancer.Correlation of ANXA1 expression with drug resistance and relapse in bladder cancerStromal proteome expression profile and muscle-invasive bladder cancer research.Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a population-based cohort study using the National Health Insurance in Taiwan.Collectives of diagnostic biomarkers identify high-risk subpopulations of hematuria patients: exploiting heterogeneity in large-scale biomarker dataThe investigation of a traditional Chinese medicine, Guizhi Fuling Wan (GFW) as an intravesical therapeutic agent for urothelial carcinoma of the bladder.A case-control study on the association between bladder cancer and prior bladder calculusKnockdown of regulator of cullins-1 (ROC1) expression induces bladder cancer cell cycle arrest at the G2 phase and senescence.Primary angiosarcoma of the bladder in a young femaleImpacts of CA9 gene polymorphisms on urothelial cell carcinoma susceptibility and clinicopathologic characteristics in TaiwanComparison of dynamic contrast-enhanced and diffusion weighted magnetic resonance image in staging and grading of carcinoma bladder with histopathological correlation.Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis.Educational opportunities in bladder cancer: increasing cystoscopic adherence and the availability of smoking-cessation programsBiomarkers for prognosis and treatment selection in advanced bladder cancer patients.An online tool for evaluating diagnostic and prognostic gene expression biomarkers in bladder cancerClaudins and ki-67: potential markers to differentiate low- and high-grade transitional cell carcinomas of the urinary bladderLong non-coding RNA UCA1 promotes glutamine metabolism by targeting miR-16 in human bladder cancer.Clinicopathologic and prognostic significance of p21 (Cip1/Waf1) expression in bladder cancer.Different patterns in the prognostic value of age for bladder cancer-specific survival depending on tumor stages.Cruciferous vegetables, isothiocyanates, and prevention of bladder cancer.Decreased expression of protein tyrosine phosphatase non-receptor type 12 is involved in the proliferation and recurrence of bladder transitional cell carcinoma.IPP51, a chalcone acting as a microtubule inhibitor with in vivo antitumor activity against bladder carcinoma.Personalized therapy for urothelial cancer: review of the clinical evidence.
P2860
Q26863299-25DF7094-15D2-4D9F-A4FB-EBFAD9F8AD81Q27013664-9A78B918-FC4F-4D2D-ABD7-98A289E63299Q28477345-68C73BE1-334F-4552-A4FE-3C9672774C19Q28552489-7526D415-C57B-4EC7-9A98-A04100932C1BQ29964599-F1CA56F8-2B04-4B6F-A4FD-FA68A0A45C32Q30234740-00BB2D6F-B13D-4F48-8242-B7D57D7DEAFDQ30414136-42DD6643-87C2-4C86-9345-39AE98CC57DCQ30485127-69B1B104-3807-44B9-8954-053307F521D4Q30968069-2F05A38A-8EE9-4230-902C-F588C128B8C9Q31028410-F632ED56-61E5-4F62-9657-79A77F63F6D4Q33609364-E23649C7-C8E2-44A7-85FD-1E962F90466AQ33778439-A9C8C6FB-C97F-43D2-8633-8CFBDA0EB425Q33943353-6ED92AC3-423A-4E6E-A24D-0E1F6436F086Q34005450-F0988846-E385-4567-BF27-06124965842DQ34065266-25EF4501-4F6B-4EB5-913C-65BA4E105FB7Q34171782-78C8CFDF-2654-4C69-A5DC-A1EA4CBB73FEQ34181385-08B0E8E9-4063-45AB-9785-C7C2EFF8F6B1Q34314461-1742950F-26AA-4FC8-B822-F7B88CED1B33Q34371175-3420D25B-128B-4E69-B223-3CA8D9207EC8Q34392967-ED19C042-8947-482B-8C53-A4E7624CB544Q34535741-46848D22-A4A9-4303-B3B0-20AB188C9DA2Q34552696-5DE9F2DB-E34F-497B-A2D1-844494A8587FQ34596187-48AC5900-57CB-4D14-B465-2E5824476BF6Q34622951-B60F8E74-E988-446A-BD70-B71BBFEDDD4CQ34717627-97D53D06-B0D1-4DDE-9891-667EEA770791Q34815912-F31269B0-634A-46CE-8F26-4C98B75FCE50Q35070536-C79A7486-7C3C-48C3-8798-82A577B73525Q35218358-8EA14CBE-0755-456A-B040-02B17034CBF3Q35407910-0A566A2E-8BF3-4D50-88E9-0BF738068094Q35545878-A34B83E1-F2BD-40A9-942B-8E569E5868FEQ35671292-972CD414-B4D7-4885-ACAB-D8F27CFB6BA8Q35678922-778C4E67-89EE-4E86-B665-2828A2709634Q35681850-10085EB3-BB3C-40AF-9DAD-7FEBE97763BAQ35776498-422ADBF1-4481-4CB5-BF8F-C1B9B798E01CQ35854027-85D9E40B-812C-411F-A0CE-E4FE0608AFE6Q35929876-8B725AB7-B0E0-49AA-B0E4-D438A16E537EQ35934829-9DE2FB54-80CF-4DDF-8E4D-14B19037855CQ35943196-6BAFEC29-12D9-4CD9-9358-7AD4E279215EQ35987440-D744124E-722A-4026-AA59-930F31E4A5AEQ36062762-528BF927-2587-49F7-B587-3535D2C9F816
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 June 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bladder cancer in 2010: how far have we come?
@en
Bladder cancer in 2010: how far have we come?
@nl
type
label
Bladder cancer in 2010: how far have we come?
@en
Bladder cancer in 2010: how far have we come?
@nl
prefLabel
Bladder cancer in 2010: how far have we come?
@en
Bladder cancer in 2010: how far have we come?
@nl
P2093
P356
P1433
P1476
Bladder cancer in 2010: how far have we come?
@en
P2093
Bruce L Jacobs
Cheryl T Lee
James E Montie
P304
P356
10.3322/CAAC.20077
P407
P577
2010-06-21T00:00:00Z